- Home
- PYPD vs PVLA Comparison
PYPD vs PVLA Comparison
Compare PYPD & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYPD
- PVLA
- Stock Information
- Founded
- PYPD 2008
- PVLA 2015
- Country
- PYPD Israel
- PVLA United States
- Employees
- PYPD N/A
- PVLA N/A
- Industry
- PYPD Medical/Dental Instruments
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- PYPD Health Care
- PVLA Health Care
- Exchange
- PYPD Nasdaq
- PVLA Nasdaq
- Market Cap
- PYPD 19.4M
- PVLA 15.9M
- IPO Year
- PYPD 2020
- PVLA N/A
- Fundamental
- Price
- PYPD $3.30
- PVLA $13.18
- Analyst Decision
- PYPD Strong Buy
- PVLA Strong Buy
- Analyst Count
- PYPD 2
- PVLA 1
- Target Price
- PYPD $10.50
- PVLA $38.00
- AVG Volume (30 Days)
- PYPD 49.0K
- PVLA 35.7K
- Earning Date
- PYPD 02-12-2025
- PVLA 02-15-2025
- Dividend Yield
- PYPD N/A
- PVLA N/A
- EPS Growth
- PYPD N/A
- PVLA N/A
- EPS
- PYPD N/A
- PVLA N/A
- Revenue
- PYPD N/A
- PVLA N/A
- Revenue This Year
- PYPD N/A
- PVLA N/A
- Revenue Next Year
- PYPD N/A
- PVLA N/A
- P/E Ratio
- PYPD N/A
- PVLA N/A
- Revenue Growth
- PYPD N/A
- PVLA N/A
- 52 Week Low
- PYPD $2.37
- PVLA $6.20
- 52 Week High
- PYPD $7.00
- PVLA $22.32
- Technical
- Relative Strength Index (RSI)
- PYPD 55.20
- PVLA N/A
- Support Level
- PYPD $2.93
- PVLA N/A
- Resistance Level
- PYPD $3.35
- PVLA N/A
- Average True Range (ATR)
- PYPD 0.24
- PVLA 0.00
- MACD
- PYPD 0.04
- PVLA 0.00
- Stochastic Oscillator
- PYPD 93.15
- PVLA 0.00
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.